News
К списку новостей
Lancet JSC has strengthened its leadership in supply of anticoagulants and preparations for anaesthesiology and resuscitation to the Russian market
In the context of the ongoing COVID-19 epidemic, the Russian pharmaceutical market has been experiencing an increase in demand for anticoagulants and preparations for anaesthesiology and resuscitation. Analysts of the Lancet pharmaceutical company has noted a tendency to increase sales in these two areas.
In 2021, anticoagulants have reached the maximum sales volume in the Russian market over the past three years; in the first half of 2021 alone, drug sales increased by 9 % compared to the same period of 2020. As expected, an active growth in demand for preparations for anaesthesiology and resuscitation occurred in 2020, and now it is in positive dynamics — there is an increase of 5 %.
“At the beginning of 2020, when there was an explosive growth in anticoagulants and preparations for anaesthesiology and resuscitation, which was associated with the influence of COVID-19 virus on the circulatory system, all the world’s largest manufacturers of these medicinal products were not ready to meet the demand, — Anton Zybin, the CEO of Lancet JSC, said. — Taking into account our stable partnerships with manufacturers, we managed to agree on the inclusion of Russia in the list of priority countries and provide our healthcare system with the necessary volumes of anticoagulants and preparations for anaesthesiology and resuscitation.”
An additional stimulus for increase in sales of anticoagulants from January 2020 was the launch of a program for secondary prevention of cardiovascular diseases, aimed at reducing cardiovascular mortality and increasing life expectancy.
“We take notice on a steady increase in demand for anticoagulants and preparations for anaesthesiology and resuscitation, which is not surprising. Unfortunately, this is primarily due to the continued spread of COVID-19 coronavirus. It is gratifying that the Ministry of Health has taken all the necessary measures to provide medical institutions with the necessary medicinal products”, — Irina Kovalchuk, Deputy Director General of Lancet JSC, said.
The main factor that has influenced the growth of the Russian pharmaceutical market in
2020-2021 is the COVID-19 pandemic. The pharmaceutical industry has showed growth even higher than it was expected at the beginning of this year. According to Lancet JSC, the total volume of the state segment of pharmaceutical market from January to September 2021 amounted to 555 billion rubles, for comparison — in the same period of 2020, the figure was 451 billion rubles.
In 2021, anticoagulants have reached the maximum sales volume in the Russian market over the past three years; in the first half of 2021 alone, drug sales increased by 9 % compared to the same period of 2020. As expected, an active growth in demand for preparations for anaesthesiology and resuscitation occurred in 2020, and now it is in positive dynamics — there is an increase of 5 %.
“At the beginning of 2020, when there was an explosive growth in anticoagulants and preparations for anaesthesiology and resuscitation, which was associated with the influence of COVID-19 virus on the circulatory system, all the world’s largest manufacturers of these medicinal products were not ready to meet the demand, — Anton Zybin, the CEO of Lancet JSC, said. — Taking into account our stable partnerships with manufacturers, we managed to agree on the inclusion of Russia in the list of priority countries and provide our healthcare system with the necessary volumes of anticoagulants and preparations for anaesthesiology and resuscitation.”
An additional stimulus for increase in sales of anticoagulants from January 2020 was the launch of a program for secondary prevention of cardiovascular diseases, aimed at reducing cardiovascular mortality and increasing life expectancy.
“We take notice on a steady increase in demand for anticoagulants and preparations for anaesthesiology and resuscitation, which is not surprising. Unfortunately, this is primarily due to the continued spread of COVID-19 coronavirus. It is gratifying that the Ministry of Health has taken all the necessary measures to provide medical institutions with the necessary medicinal products”, — Irina Kovalchuk, Deputy Director General of Lancet JSC, said.
The main factor that has influenced the growth of the Russian pharmaceutical market in
2020-2021 is the COVID-19 pandemic. The pharmaceutical industry has showed growth even higher than it was expected at the beginning of this year. According to Lancet JSC, the total volume of the state segment of pharmaceutical market from January to September 2021 amounted to 555 billion rubles, for comparison — in the same period of 2020, the figure was 451 billion rubles.